Thalidomide
CLINICAL USE
Untreated multiple myeloma in patients >65 or who are ineligible for high dose chemotherapy, in combination with either melphalan and prednisone, or cyclophosphamide and dexamethasone (Unlicensed indications): Erythema nodusum leprosum Lupus erythematosus, aphthous ulceration, stomatitis, graft-versus-host disease, AIDS-associated waste syndrome, rheumatoid arthritis and other acute inflammatory conditions
DOSE IN NORMAL RENAL FUNCTION
200 mg daily Unlicensed dose: 50–800 mg daily
PHARMACOKINETICS
Molecular weight                           : 258.2 %Protein binding                           : 55–66 %Excreted unchanged in urine     : <0.7 Volume of distribution (L/kg)       : 166 litres half-life – normal/ESRD (hrs)      : 5–7/Unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                : Unlikely to be dialysed. Dose as in normal renal function HD                     : Unlikely to be dialysed. Dose as in normal renal function HDF/high flux   : Not dialysed. Dose as in normal renal function CAV/VVHD      : Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Thalidomide enhances the effects of barbiturates, alcohol, chlorpromazine and reserpine Use with caution with other drugs that can cause peripheral neuropathy ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
– Comments
– OTHER INFORMATION
Major route of elimination is non-renal (i.e. by spontaneous non-enzymatic hydrolytic cleavage) therefore normal doses may be given in renal failure Has been used to treat uraemic pruritus in haemodialysis patients unresponsive to other therapy. (Silva SR. Thalidomide for the treatment of uraemic pruritus: a crossover randomised double-blind trial. Nephron. 1994; 67(3): 270–3.) Can cause unexplained hyperkalaemia. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home